SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify is rallying after its Q3 report, with traders focusing on premium subscriber growth, improving gross margin and a stronger Q4 profit outlook despite a revenue and EPS miss. Bulls see the forward guidance as the key signal, while bears question the spending and the sharp move higher despite the missed estimates.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASMLs quarterly results and outlook are driving attention: management described strong AI-related demand that could exceed planned equipment supply, while raising its sales outlook. The shares have nevertheless sold off, prompting debate over a sell the news reaction and whether elevated expectations, valuation concerns, or broader weakness in semiconductor stocks outweighed the upbeat demand signal.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, particularly strong refining performance and record refinery throughput, are the main focus. Traders are celebrating the earnings beat and new highs, while some question whether elevated refining margins can last and whether the rally is overextended.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The Other segment includes DLP products, calculators, and custom application-specific integrated circuits products. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments strong Q3 results and above-consensus Q4 outlook are driving discussion, alongside the stocks recent rally and breakout. Traders are split between viewing the results and call buying as bullish and treating put activity and the pullback as hedging or profit-taking.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs quarterly results and its growing data-center business are the main focus, with traders highlighting the Amazon supply agreement and expanding backlog as support for its AI infrastructure story. Views are mixed: some see strong commercial growth and an earnings beat, while others point to a sales shortfall, unchanged full-year guidance, thinner commercial margins and profit-taking.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Traders are focused on Compounds institutional-market rollout and reported treasury-backed expansion, which bulls see as a potential boost to its DeFi business. Others remain skeptical, pointing to COMPs weak performance versus other crypto assets and its difficulty sustaining gains.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Discussion centers on Pyths revenue-linked buyback policy and Nasdaq data distribution, which traders cite as evidence of growing utility and RWA adoption. Optimism about a recovery and a teased quarterly announcement is tempered by concerns about token supply, volatility, and whether revenue-driven demand will be enough.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rival will erode PAPZIMEOS sales, citing its potential to reduce surgeries while also pointing to Precigens first-mover advantage, full-approval status, and Inovios commercialization and funding challenges.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion is dominated by reports of a major Binance security breach and stolen crypto, prompting concerns about customer fund safety, suspended withdrawals, and possible spillover across crypto markets. Traders debate whether Binance can cover losses and whether the incident signals deeper exchange risks, while some point to frozen assets and the tokens relative resilience.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as crude oil trades on U.S.-Iran tensions and risks to Strait of Hormuz shipping, with traders debating whether supply disruptions will sustain prices or a diplomatic deal will unwind the risk premium. Bulls emphasize constrained supply and fuel shortages, while bears point to possible de-escalation, oversupply and inventory builds, and volatility decay in the leveraged fund.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Key PointsAdded 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price...

HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...

Trevi Therapeutics Q1 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering.

Clinical program updates and upcoming trial starts
Pres...

Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

Equity

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Underwriters were given a 30-day option to purchase up to 1.74 million additional shares.</li><li>Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary fibrosis.</li><li>The company plans to launch two late-stage clinical trials starting in the second quarter of 2026.</li></ul>Shares of Trevi Therapeutics, Inc. (TRVI) jumped 5% on Friday to an all-time high after the biotech firm priced its $150 million underwritten public offering at $13 per share.<a href="https://stocktwits.com/symbol/TRVI">TRVI shares</a> are heading for a fifth consecutive session of gains, rising nearly 20% over the course of the rally.While Trevi offered 11.6 million shares at $13 per share, it also granted underwriters a 30-day option to purchase up to 1.74 million additional shares that could fetch up to $22.5 million. The offering is expected to close around April 20, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier. Message volumes soared a whopping 600% on the platform over the past 24 hours, according to Stocktwits data.One user called the price action “strange” and questioned if it was driven by a “small squeeze.”<stembedurl>https://stocktwits.com/abcdzepeda/message/650605154</stembedurl>Another user, who commented before the $13 per share offer was disclosed, said the dilution seemed unnecessary.<stembedurl>https://stocktwits.com/socalBB/message/650528771</stembedurl><h2 class="st-heading-2">Trevi Prepares To Launch Late-Stage Trials For Chronic Cough Treatment</h2>Trevi Therapeutics is currently developing Haduvio, its treatment for chronic cough in patients with conditions such as idiopathic pulmonary fibrosis, interstitial lung disease, and refractory chronic cough.Last month, the firm <a href="https://stocktwits.com/news-articles/markets/equity/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE">announced</a> plans to launch two late-stage clinical trials for Haduvio following discussions with the U.S. Food and Drug Administration (FDA). The first trial is expected to begin in the second quarter of 2026, with the second starting later in the year.Both studies will be randomized and placebo-controlled, testing the drug’s safety and effectiveness. One trial will enroll around 300 patients, while the other will include about 130, Trevi added.The stock has seen heavy buying interest over the past year, surging more than 165%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$TRVI Is anyone paying attention to the volume this week? 5m shares yesterday and today. And both days with >2m shares traded AH.  And the call activity. Someone is buying in.

Biotech

$TRVI This is a sleepy town.  Is everyone out of this thing because it's taking a whipping.  Any thoughts?

Jeffrey L. Crane

$TRVI It’s been a mess lately, similar to a lot of biotechs. But the volume this week has been insane.

BMO Capital reiterated $TRVI Outperform-$36 and said -- TRVI Stands Alone in RCC Following Nocion Study Failure; Focus Now Turns to SSRE 
$MRK $RHHBY 𝑵̶𝒐̶𝒄̶𝒊̶𝒐̶𝒏̶𝑻̶𝒙̶  𝑮̶𝑺̶𝑲̶  
BMO Capital added—Nocion's Phase 2b ASPIRE failure strengthens the competitive setup for Trevi. 
Taplucainium missed its cough-frequency endpoint amid a large, variable placebo response, suggesting its peripheral-focused mechanism may have been insufficient to deliver meaningful efficacy in chronic cough. 
 
The result removes a potential once-daily inhaled competitor while highlighting Haduvio's differentiated central and peripheral activity and existing proof-of-concept across RCC and IPF-related cough. 
 
We view the outcome as supportive for Trevi shares, with attention now turning to the 4Q26 LAKE sample-size re-estimation and multiple clinical readouts expected in 2H27.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRVI Trevi Therapeutics Inc

Fundamentals

Latest TRVI News